{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:18Z","timestamp":1787041698976,"version":"build-2736575974"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004271","name":"University of Rome La Sapienza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119083","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:14:40Z","timestamp":1782400480000},"page":"119083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Twin engines of viral replication: Medicinal chemistry insights on SARS-CoV-2 nsp12 and nsp13"],"prefix":"10.1016","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-612X","authenticated-orcid":false,"given":"Valentina Noemi","family":"Madia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Patacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saccoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zarbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Arpacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-9029","authenticated-orcid":false,"given":"Roberta","family":"Costi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/v13010049","article-title":"Computational analysis of SARS-CoV-2 and SARS-like coronavirus diversity in human, bat and pangolin populations","volume":"13","author":"Dimonaco","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib2","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12964-023-01104-5","article-title":"Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases","volume":"21","author":"Kakavandi","year":"2023","journal-title":"Cell Commun. Signal."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119083_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107774","article-title":"Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2","volume":"31","author":"Peng","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13578-021-00643-z","article-title":"SARS-CoV-2: from its discovery to genome structure, transcription, and replication","volume":"11","author":"Brant","year":"2021","journal-title":"Cell Biosci."},{"issue":"6492","key":"10.1016\/j.ejmech.2026.119083_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"7819","key":"10.1016\/j.ejmech.2026.119083_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119083_bib8","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1038\/sj.emboj.7601368","article-title":"A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus","volume":"25","author":"Imbert","year":"2006","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-020-02439-0","article-title":"Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach","volume":"18","author":"Aftab","year":"2020","journal-title":"J. Transl. Med."},{"issue":"28","key":"10.1016\/j.ejmech.2026.119083_bib10","doi-asserted-by":"crossref","first-page":"E4005","DOI":"10.1073\/pnas.1602591113","article-title":"Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation","volume":"113","author":"Shu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib11","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.3390\/v7082829","article-title":"RNA-dependent RNA polymerases of picornaviruses: from the structure to regulatory mechanisms","volume":"7","author":"Ferrer-Orta","year":"2015","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2020.11.016","article-title":"Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis","volume":"184","author":"Yan","year":"2021","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119083_bib13","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1093\/nar\/gkab677","article-title":"NMPylation and de-NMPylation of SARS-CoV-2 nsp9 by the NiRAN domain","volume":"49","author":"Wang","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19","volume":"31","author":"Vicenti","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6498","key":"10.1016\/j.ejmech.2026.119083_bib15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA proofreading: molecular basis and therapeutic targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.167973","article-title":"Fidelity of ribonucleotide incorporation by the SARS-CoV-2 replication complex","volume":"435","author":"Yin","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119083_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","volume":"189","author":"De Clercq","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.1862","article-title":"Off-label therapies for COVID-19-Are we all in this together?","volume":"108","author":"Alpern","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119083_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115757","article-title":"COVID-19 therapy: what weapons do we bring into battle?","volume":"28","author":"de Almeida","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17460441.2021.1912733","article-title":"Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?","volume":"16","author":"Gil","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119083_bib24","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.drudis.2022.02.012","article-title":"Efficacy of repurposed antiviral drugs: lessons from COVID-19","volume":"27","author":"Martinez","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119083_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.ejmech.2026.119083_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2020.11.043","article-title":"Remdesivir: from Ebola to COVID-19","volume":"538","author":"Santoro","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib27","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2020","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119083_bib28","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119083_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"396","key":"10.1016\/j.ejmech.2026.119083_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib35","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat. Commun."},{"issue":"643","key":"10.1016\/j.ejmech.2026.119083_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"Sch\u00e4fer","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119083_bib37","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41401-022-00895-6","article-title":"Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects","volume":"43","author":"Qian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of Covid-19","volume":"388","author":"Cao","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1473-3099(23)00577-7","article-title":"Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study","volume":"24","author":"Fan","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119083_bib40","first-page":"1","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2026.119083_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130243","article-title":"Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment","volume":"124","author":"Zheng","year":"2025","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12985-025-02631-y","article-title":"Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial","volume":"22","author":"Bai","year":"2025","journal-title":"Virol. J."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119083_bib43","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.1021\/acs.jmedchem.4c00899","article-title":"Discovery of GS-7682, a novel 4'-Cyano-Modified C-Nucleoside prodrug with broad activity against Pneumo- and picornaviruses and efficacy in RSV-infected African green monkeys","volume":"67","author":"Siegel","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119083_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog."},{"issue":"656","key":"10.1016\/j.ejmech.2026.119083_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119083_bib47","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 adaptive COVID-19 treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119083_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106264","article-title":"Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases","volume":"242","author":"Ichikawa","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119083_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib50","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119083_bib51","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: a new candidate for COVID\u201019 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-D-N 4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Diseases"},{"key":"10.1016\/j.ejmech.2026.119083_bib57","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.935952","article-title":"Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejmech.2026.119083_bib59","series-title":"Lagevrio Letter of Authorization","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119083_bib60","series-title":"Science","article-title":"A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm","author":"Service","year":"2021"},{"key":"10.1016\/j.ejmech.2026.119083_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119083_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115279","article-title":"An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges","volume":"205","author":"Xu","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/v14010008","article-title":"Activity of galidesivir in a hamster model of SARS-CoV-2","volume":"14","author":"Taylor","year":"2021","journal-title":"Viruses"},{"issue":"7496","key":"10.1016\/j.ejmech.2026.119083_bib64","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2013a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Infect. Public Health"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib66","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir: a review in chronic hepatitis C","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119083_bib68","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkab072","article-title":"In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19","volume":"76","author":"Sacramento","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119083_bib69","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73641-9","article-title":"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir","volume":"10","author":"Jockusch","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-022-28113-1","article-title":"A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase","volume":"13","author":"Shannon","year":"2022","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119083_bib73","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2217\/fvl-2023-0115","article-title":"Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)","volume":"18","author":"Horga","year":"2023","journal-title":"Future Virol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib74","first-page":"33","article-title":"Advances in nucleotide antiviral development from scientific discovery to clinical applications: tenofovir disoproxil fumarate for hepatitis B","volume":"1","author":"Lou","year":"2013","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119083_bib75","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/ph14050454","article-title":"Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection","volume":"14","author":"Zanella","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119083_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115292","article-title":"Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2","volume":"252","author":"Bekheit","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib78","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/19390211.2021.2006387","article-title":"Plant-derived natural non-nucleoside analog inhibitors (NNAIs) against RNA-dependent RNA polymerase complex (nsp7\/nsp8\/nsp12) of SARS-CoV-2","volume":"20","author":"Naidu","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"10.1016\/j.ejmech.2026.119083_bib80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.plaphy.2021.05.023","article-title":"The role of quercetin in plants","volume":"166","author":"Singh","year":"2021","journal-title":"Plant Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14664-2","article-title":"Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase","volume":"12","author":"Munaf\u00f2","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/1751-7915.13675","article-title":"Repositioning microbial biotechnology against COVID-19: the case of microbial production of flavonoids","volume":"14","author":"Goris","year":"2021","journal-title":"Microb. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib83","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/14756366.2016.1265519","article-title":"Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors","volume":"32","author":"Park","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/acsptsci.1c00253","article-title":"Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities","volume":"5","author":"Corona","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119083_bib85","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1002\/ptr.7486","article-title":"Comparative evaluation of flavonoids reveals the superiority and promising inhibition activity of silibinin against SARS\u2010CoV\u20102","volume":"36","author":"Hamdy","year":"2022","journal-title":"Phytother Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib86","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/microorganisms9050893","article-title":"Baicalein and baicalin inhibit SARS-CoV-2 RNA-dependent-RNA polymerase","volume":"9","author":"Zandi","year":"2021","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib87","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/biomedicines10051170","article-title":"Natural polyphenols, 1, 2, 3, 4, 6-O-pentagalloyglucose and proanthocyanidins, as broad-spectrum anticoronaviral inhibitors targeting Mpro and RdRp of SARS-CoV-2","volume":"10","author":"Jin","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119083_bib88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2018.01.030","article-title":"Corilagin, a promising medicinal herbal agent","volume":"99","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib89","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.apsb.2021.02.011","article-title":"Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.virs.2023.04.008","article-title":"Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase","volume":"38","author":"Zhang","year":"2023","journal-title":"Virol. Sin."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101362","article-title":"A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein","volume":"297","author":"Littler","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154266","article-title":"Lycorine and organ protection: review of its potential effects and molecular mechanisms","volume":"104","author":"Xiao","year":"2022","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119083_bib93","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00023-19","article-title":"High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses","volume":"93","author":"Shen","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119083_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153440","article-title":"Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections","volume":"86","author":"Jin","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119083_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116180","article-title":"Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp","volume":"171","author":"Zhou","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119083_bib96","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/nu5093367","article-title":"Flavonoid bioavailability and attempts for bioavailability enhancement","volume":"5","author":"Thilakarathna","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2026.119083_bib97","series-title":"Role of Phenolic Phytochemicals in Diabetes Management","article-title":"Pharmacokinetics and pharmacodynamics of polyphenols","author":"Hoda","year":"2019"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01168-19","article-title":"100 years of suramin","volume":"64","author":"Wiedemar","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib99","doi-asserted-by":"crossref","first-page":"e00900","DOI":"10.1128\/AAC.00900-20","article-title":"Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle","volume":"64","author":"Salgado-Benvindo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","article-title":"Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119083_bib101","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.actbio.2018.12.010","article-title":"Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles","volume":"84","author":"Cheng","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejmech.2026.119083_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101973","article-title":"SARS-CoV-2 replication and drug discovery","volume":"77","author":"Nazir","year":"2024","journal-title":"Mol. Cell. Probes"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib103","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/v13050873","article-title":"The repurposed drugs suramin and quinacrine cooperatively inhibit SARS-CoV-2 3CLpro in vitro","volume":"13","author":"Eberle","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12985-016-0607-2","article-title":"Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry","volume":"13","author":"Hen\u00df","year":"2016","journal-title":"Virol. J."},{"key":"10.1016\/j.ejmech.2026.119083_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105209","article-title":"2-((1H-indol-3-yl) thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors","volume":"196","author":"Zhao","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119083_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113622","article-title":"Discovery and optimization of 2-((1H-indol-3-yl) thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors","volume":"223","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib107","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2019.03.004","article-title":"Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions","volume":"167","author":"Cannalire","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119083_bib108","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/v13081585","article-title":"Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication","volume":"13","author":"Dejmek","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib109","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3762\/bjoc.20.91","article-title":"Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics","volume":"20","author":"T\u00f3th","year":"2024","journal-title":"Beilstein J. Org. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib110","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/acsinfecdis.1c00083","article-title":"Quinoline and quinazoline derivatives inhibit viral RNA synthesis by SARS-CoV-2 RdRp","volume":"7","author":"Zhao","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100046","article-title":"Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay","volume":"1","author":"Uppal","year":"2022","journal-title":"Cell Insight"},{"issue":"22","key":"10.1016\/j.ejmech.2026.119083_bib112","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.3390\/molecules27227732","article-title":"Structural homology-based drug repurposing approach for targeting NSP12 SARS-CoV-2","volume":"27","author":"Aljuaid","year":"2022","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119083_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710171","article-title":"Antiviral activity of N1, N3-disubstituted uracil derivatives against SARS-CoV-2 variants of concern","volume":"23","author":"Siniavin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119083_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117179","article-title":"Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors","volume":"80","author":"Brindani","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib115","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jsps.2022.02.014","article-title":"In silico evaluation of Vitis amurensis Rupr. Polyphenol compounds for their inhibition potency against COVID-19 main enzymes m(pro) and RdRp","volume":"30","author":"Souid","year":"2022","journal-title":"Saudi Pharm. J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib116","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/molecules28010160","article-title":"Identification of polyphenol derivatives as novel SARS-CoV-2 and DENV non-nucleoside RdRp inhibitors","volume":"28","author":"Gao","year":"2022","journal-title":"Molecules"},{"issue":"30","key":"10.1016\/j.ejmech.2026.119083_bib117","doi-asserted-by":"crossref","first-page":"27056","DOI":"10.1021\/acsomega.3c02079","article-title":"Discovery of hybrid thiouracil\u2013coumarin conjugates as potential novel Anti-SARS-CoV-2 agents targeting the virus's polymerase \u201cRdRp\u201d as a confirmed interacting biomolecule","volume":"8","author":"Vishwanath","year":"2023","journal-title":"ACS Omega"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119083_bib118","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1042\/BCJ20210200","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12\/7\/8 RNA-dependent RNA polymerase","volume":"478","author":"Bertolin","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119083_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844749","article-title":"Identifying small-molecule inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase by establishing a fluorometric assay","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119083_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199164","article-title":"Anthracyclines inhibit SARS-CoV-2 infection","volume":"334","author":"Wang","year":"2023","journal-title":"Virus Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119083_bib121","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib122","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib123","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/acs.jmedchem.5b01009","article-title":"Can invalid bioactives undermine natural product-based drug discovery?","volume":"59","author":"Bisson","year":"2016","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119083_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110115","article-title":"Suramin inhibits Hsp104 ATPase and disaggregase activity","volume":"9","author":"Torrente","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119083_bib125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/biom16040527","article-title":"Suramin interactions across biological systems: from molecular targets to therapeutic implications","volume":"16","author":"Catalano","year":"2026","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib126","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acs.jcim.6b00465","article-title":"Phantom PAINS: problems with the utility of alerts for pan-assay INterference CompoundS","volume":"57","author":"Capuzzi","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib127","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/0889311X.2024.2309494","article-title":"What a twist: structural biology of the SARS-CoV-2 helicase nsp13","volume":"29","author":"Horrell","year":"2023","journal-title":"Crystallogr. Rev."},{"key":"10.1016\/j.ejmech.2026.119083_bib128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virusres.2014.12.001","article-title":"What we know but do not understand about nidovirus helicases","volume":"202","author":"Lehmann","year":"2015","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102980","article-title":"Biochemical analysis of SARS-CoV-2 Nsp13 helicase implicated in COVID-19 and factors that regulate its catalytic functions","volume":"299","author":"Sommers","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13578-022-00770-1","article-title":"SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1","volume":"12","author":"Fung","year":"2022","journal-title":"Cell Biosci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib131","article-title":"A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance","volume":"14","author":"Grimes","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.119083_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199401","article-title":"The coronavirus helicase in replication","volume":"346","author":"Grimes","year":"2024","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib133","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41467-021-25166-6","article-title":"Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase","volume":"12","author":"Newman","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119083_bib134","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1093\/nar\/gkz409","article-title":"Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis","volume":"47","author":"Jia","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib135","article-title":"Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies","volume":"9","author":"Mehyar","year":"2023","journal-title":"J. Virus Erad."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib136","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/v13081547","article-title":"A helicase-primase inhibitor, for the optimal treatment of Herpes zoster","volume":"13","author":"Shiraki","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib137","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119083_bib138","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/cb500512z","article-title":"Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication","volume":"9","author":"Mukherjee","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119083_bib139","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1021\/acs.jmedchem.6b00486","article-title":"Fragment-based discovery of dual JC virus and BK virus helicase inhibitors","volume":"59","author":"Bonafoux","year":"2016","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib140","doi-asserted-by":"crossref","first-page":"e00505","DOI":"10.1128\/mSystems.00505-20","article-title":"Comparative genomic analysis of rapidly evolving SARS-CoV-2 reveals mosaic pattern of phylogeographical distribution","volume":"5","author":"Kumar","year":"2020","journal-title":"mSystems"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib141","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1062936X.2020.1857437","article-title":"Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase","volume":"32","author":"Mehyar","year":"2021","journal-title":"SAR QSAR Environ. Res."},{"issue":"39","key":"10.1016\/j.ejmech.2026.119083_bib142","doi-asserted-by":"crossref","first-page":"15664","DOI":"10.1021\/acs.inorgchem.2c02685","article-title":"Structural reshaping of the zinc-finger domain of the SARS-CoV-2 nsp13 protein using bismuth(III) ions: a multilevel computational study","volume":"61","author":"Tolbatov","year":"2022","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib143","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ijbiomac.2020.09.138","article-title":"Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)","volume":"163","author":"Ugurel","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib144","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s42485-021-00067-w","article-title":"Screening of FDA-approved compound library identifies potential small-molecule inhibitors of SARS-CoV-2 non-structural proteins NSP1, NSP4, NSP6 and NSP13: molecular modeling and molecular dynamics studies","volume":"12","author":"Sundar","year":"2021","journal-title":"J. Protein Proteonomics"},{"key":"10.1016\/j.ejmech.2026.119083_bib145","article-title":"In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors","volume":"21","author":"Gurung","year":"2020","journal-title":"Gene Rep"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib146","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12250-020-00242-1","article-title":"SARS-Coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts","volume":"35","author":"Shu","year":"2020","journal-title":"Virol. Sin."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119083_bib147","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41564-020-00802-x","article-title":"Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters","volume":"5","author":"Yuan","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119083_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127958","article-title":"Development of new disulfiram analogues as ALDH1a1-selective inhibitors","volume":"40","author":"Omran","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119083_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2021.108209","article-title":"Development of ebselen for the treatment of sensorineural hearing loss and tinnitus","volume":"413","author":"Kil","year":"2022","journal-title":"Hear. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib150","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acsptsci.1c00106","article-title":"Correction to \"Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram\/Ebselen and Remdesivir\"","volume":"4","author":"Chen","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib151","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15898-w","article-title":"SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysis","volume":"12","author":"Samy","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib152","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41467-024-45690-5","article-title":"Cepharanthine analogs mining and genomes of Stephania accelerate anti-coronavirus drug discovery","volume":"15","author":"Leng","year":"2024","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.ejmech.2026.119083_bib153","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1021\/acs.jpclett.0c02421","article-title":"Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase","volume":"11","author":"White","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib154","first-page":"493","article-title":"Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro","volume":"118","author":"Zhang","year":"2005","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119083_bib155","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/1062936X.2021.1993995","article-title":"Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay","volume":"32","author":"Mehyar","year":"2021","journal-title":"SAR QSAR Environ. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106499","article-title":"Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice","volume":"59","author":"Muturi","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2026.119083_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1062352","article-title":"Therapeutic potential of compounds targeting SARS-CoV-2 helicase","volume":"10","author":"Halma","year":"2022","journal-title":"Front. Chem."},{"issue":"7859","key":"10.1016\/j.ejmech.2026.119083_bib158","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119083_bib159","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.bmcl.2009.07.009","article-title":"Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase\/helicase by dihydroxychromone derivatives","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119083_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105697","article-title":"Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication","volume":"217","author":"Corona","year":"2023","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119083_bib161","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543776.2021.1884224","article-title":"Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents","volume":"31","author":"Spratt","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119083_bib162","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1042\/BCJ20210201","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase","volume":"478","author":"Zeng","year":"2021","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib163","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1107\/S2059798325004498","article-title":"Myricetin-bound crystal structure of the SARS-CoV-2 helicase NSP13 facilitates the discovery of novel natural inhibitors","volume":"81","author":"Kloskowski","year":"2025","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.119083_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105389","article-title":"Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro","volume":"206","author":"Lu","year":"2022","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119083_bib165","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","article-title":"Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase","volume":"56","author":"Adedeji","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib166","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbrc.2014.09.113","article-title":"Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format","volume":"453","author":"Basavannacharya","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119083_bib167","doi-asserted-by":"crossref","first-page":"e2011","DOI":"10.1073\/pnas.1601089113","article-title":"Suramin inhibits cullin-RING E3 ubiquitin ligases","volume":"113","author":"Wu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091765","article-title":"Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds","volume":"9","author":"Croci","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib169","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/AAC.02994-14","article-title":"Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses","volume":"58","author":"Adedeji","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj4526","article-title":"Toward wide-spectrum antivirals against coronaviruses: molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors","volume":"8","author":"Perez-Lemus","year":"2022","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119083_bib171","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","article-title":"Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds","volume":"38","author":"Tomassini","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib172","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/jm400674a","article-title":"Inhibiting the HIV integration process: past, present, and the future","volume":"57","author":"Di Santo","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119083_bib173","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.antiviral.2016.09.008","article-title":"New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H","volume":"134","author":"Corona","year":"2016","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119083_bib174","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bmcl.2009.02.010","article-title":"Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase\/helicase","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"14","key":"10.1016\/j.ejmech.2026.119083_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500205","article-title":"Structure-activity relationships of new 1-Aryl-1H-Indole derivatives as SARS-CoV-2 Nsp13 inhibitors","volume":"20","author":"Madia","year":"2025","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119083_bib176","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2539445","article-title":"N-alkyl and N-benzyl indoles are anti-SARS-CoV-2 agents and nsp13 inhibitors","volume":"40","author":"Albano","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib177","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/acsmedchemlett.2c00123","article-title":"Discovery of 2-Phenylquinolines with broad-spectrum anti-coronavirus activity","volume":"13","author":"Nizi","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119083_bib178","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1039\/D3RA00056G","article-title":"Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents","volume":"13","author":"Kumar","year":"2023","journal-title":"RSC Adv."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119083_bib179","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/acsinfecdis.2c00165","article-title":"Kinetic characterization of SARS-CoV-2 nsp13 ATPase activity and discovery of small-molecule inhibitors","volume":"8","author":"Yazdi","year":"2022","journal-title":"ACS Infect. Dis."},{"issue":"21","key":"10.1016\/j.ejmech.2026.119083_bib180","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.3390\/molecules27217522","article-title":"Targeting SARS-CoV-2 nsp13 helicase and assessment of druggability pockets: identification of two potent inhibitors by a multi-site in silico drug repurposing approach","volume":"27","author":"Romeo","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119083_bib181","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/cells12050776","article-title":"CFTR inhibitors display in vitro antiviral activity against SARS-CoV-2","volume":"12","author":"Lagni","year":"2023","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119083_bib182","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1021\/acschembio.4c00244","article-title":"A repurposed drug interferes with nucleic acid to inhibit the dual activities of coronavirus Nsp13","volume":"19","author":"Soper","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119083_bib183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009969","article-title":"A phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model","volume":"1","author":"Erdem","year":"2021","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119083_bib184","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acschembio.4c00458","article-title":"Analogs of NIH molecular probe ML283 are potent SARS-CoV-2 helicase inhibitors","volume":"20","author":"Frick","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119083_bib185","article-title":"Discovery of 4-((quinolin-8-ylthio) methyl) benzamide derivatives as a new class of SARS-CoV-2 nsp13 inhibitors","volume":"122","author":"Fan","year":"2025","journal-title":"BMC Lett"},{"issue":"14","key":"10.1016\/j.ejmech.2026.119083_bib186","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.3390\/molecules26144230","article-title":"Ebselen and analogues: pharmacological properties and synthetic strategies for their preparation","volume":"26","author":"Santi","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119083_bib187","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acs.jnatprod.5b00947","article-title":"Feeling Nature's PAINS: natural products, natural product drugs, and pan assay interference compounds (PAINS)","volume":"79","author":"Baell","year":"2016","journal-title":"J. Nat. Prod."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:08:43Z","timestamp":1787040523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":186,"alternative-id":["S0223523426005283"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119083","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twin engines of viral replication: Medicinal chemistry insights on SARS-CoV-2 nsp12 and nsp13","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119083"}}